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Background: Adjuvant chemotherapy for stage III colon cancer is internationally accepted as standard treatment
with established efficacy. Several oral fluorouracil (5-FU) derivatives with different properties are available in Japan,
but which drug is the most appropriate for each patient has not been established. Although efficacy prediction of
5-FU derivatives using expression of 5-FU activation/metabolism enzymes in tumors has been studied, it has not
been clinically applied.
Methods/design: The B-CAST study is a multicenter, prospective cohort study aimed to identify the patients who
benefit from adjuvant chemotherapy with each 5-FU regimen, through evaluating the relationship between tumor
biomarker expression and treatment outcome. The frozen tumor specimens of patients with stage III colon cancer
who receives postoperative adjuvant chemotherapy are examined. Protein expression of thymidine phosphorylase
(TP), dihydropyrimidine dehydrogenase (DPD), epidermal growth factor receptor (EGFR), and vascular endothelial
growth factor (VEGF) are evaluated using enzyme-linked immunosorbent assay (ELISA). mRNA expression of TP,
DPD, thymidylate synthase (TS) and orotate phosphoribosyl transferase (OPRT) are evaluated using reverse
transcription polymerase chain reaction (RT-PCR). The patients’ clinical data reviewed are as follow: demographic
and pathological characteristics, regimen, drug doses and treatment duration of adjuvant therapy, types and
severity of adverse events, disease free survival, relapse free survival and overall survival. Then, relationships among
the protein/mRNA expression, clinicopathological characteristics and the treatment outcomes are analyzed for each
5-FU derivative.
Discussion: A total of 2,128 patients from the 217 institutions were enrolled between April 2009 and March 2012.
The B-CAST study demonstrated that large-scale, multicenter translational research using frozen samples was
feasible when the sample shipment and Web-based data collection were well organized. The results of the study
will identify the predictors of benefit from each 5-FU derivative, and will contribute to establish the “personalized
therapy” in adjuvant chemotherapy for colon cancer.
Trial registration: ClinicalTrials.gov: NCT00918827, UMIN Clinical Trials Registry (UMIN-CTR) UMIN000002013
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Colorectal cancer (CRC) is the second most common
cancer and the third most fatal cancer in Japan. In par-
ticular, colon cancer has been increasing in recent years
[1,2]. Postoperative adjuvant chemotherapy for patients
with stage III colon cancer is internationally accepted as
a standard care to improve survival, and there are sev-
eral options as treatment regimens. The Guidelines 2010
for the Treatment of Colorectal Cancer published by the
Japanese Society for Cancer of the Colon and Rectum
(JSCCR) [3] recommend four regimens as adjuvant ther-
apy for stage III disease: 5-fluorouracil (5-FU)/leucovorin
(LV), UFT/LV, capecitabine, 5-FU/LV (or capecitabine) +
oxaliplatin. In addition, S-1 [4] or S-1 + oxaliplatin [5]
are used on an experimental basis.
In Japan, oral 5-FU derivatives (5-FUs) have been pre-
ferred because of their convenience, leading to the devel-
opment of several oral 5-FUs with different properties.
UFT (Taiho Pharmaceutical Co., Ltd., Tokyo, Japan) is
a combination drug of tegafur, a prodrug of 5-FU, and ura-
cil, an inhibitor of dihydropyrimidine dehydrogenase
(DPD) that is a degradative enzyme for 5-FU, in a molar
ratio of 4:1 [6]. Concomitant use of folic acid derivative
LV with UFT promotes stabilising the ternary complex
and augmenting the inhibition of thymidylate synthase
(TS) by 5-FU. Capecitabine (Chugai Pharmaceutical
Co., Ltd., Tokyo, Japan) is designed to be specifically
transformed from 5’-deoxy-5-fluorouridine (5’-DFUR) to
5-FU by thymidine phosphorylase (TP), which is in higher
concentrations in tumor tissues than in normal tissues,
with the aim of reducing the gastrointestinal and
hematological toxicities of 5-FU [7]. S-1 (Taiho Pharma-
ceutical Co., Ltd.) combines tegafur, gimeracil and oteracil,
in a molar ratio of 1:0.4:1. Gimeracil, a DPD inhibitor, is
about 200-fold more potent than uracil. Oteracil inhibits
the conversion of 5-FU to active metabolites in the gastro-
intestinal tract, resulting in reduction of gastrointestinal
toxicity of 5-FU [8]. These preparations have different
profiles of adverse event (AE). UFT is reported to be often
associated with liver dysfunction in Japanese patients
[4,9]. A most common AE of capecitabine is hand-foot
syndrome (HFS) [10]. S-1 often causes mild hematological
toxicity and fatigue [4].
Multiple options are available for adjuvant therapy
with 5-FUs for colon cancer, however, which drug is the
most appropriate for each patient has not been
established. The efficacy of 5-FUs is reported to be re-
lated to the expression of enzymes that correlate to
5-FU activation/metabolism in tumors and/or blood.
Ichikawa et al. [11] reported that of 37 patients with
metastatic CRC, UFT/LV was useful in those with low
tumor mRNA expression of TS, DPD, and orotate
phosphoribosyl transferase (OPRT). Nishimura et al.
[12] disclosed that from analysis of 88 patients withDukes B/C CRC who received 5’-DFUR therapy, those
with high tumor TP protein expression in enzyme-
linked immunosorbent assay (ELISA) showed better
prognosis. On the other hand, TP is also known as a
platelet-delivered endothelial cell growth factor, and it
has been reported that metastatic CRC with high tumor
mRNA levels of TP had poor prognosis [13].
Prediction of efficacy in 5-FUs treatment has been stud-
ied [14] but has not been clinically applied yet, because of
no large prospective studies or because of difficulty in
measurement as point of versatility and cost. “Personal-
ized therapy”, which means to select the best option from
different treatments based on individual patients’ factors,
could improve not only the efficacy but also the safety, pa-
tient’s quality of life and cost-effectiveness in adjuvant
therapy for colon cancer.
We therefore conducted a prospective cohort study
named the B-CAST study (Biomarker-cohort study of
adjuvant chemotherapy for stage III colon cancer), to
identify the patients who benefit from adjuvant chemo-
therapy with each 5-FU derivative, through evaluating
the relationships between tumor biomarker expression
and treatment outcome.
Methods/design
The design of study
This study is a multicenter, prospective cohort study
evaluating the relationships between tumor biomarker
expression and treatment outcome of adjuvant chemo-
therapy in patients with stage III colon cancer. In this
paper, the disease stage is described by the 7th UICC–
TNM classification system.
Six candidate biomarkers are selected for this study:
TP, DPD, TS and OPRT as key enzymes correlating to 5-
FU activation/metabolism [11-14], and epidermal growth
factor receptor (EGFR) and vascular endothelial growth
factor (VEGF) as promising markers which are corre-
lated to tumor proliferation and/or metastasis of CRC
[15-18] and which are already in clinical use as targets
of the molecular-target drug.
The frozen tumor samples from surgical specimen
of patients with stage III colon cancer who receives post-
operative adjuvant chemotherapy are examined. Protein
expression of TP, DPD, EGFR and VEGF are evaluated
using ELISA, and mRNA expression of TP, DPD, TS and
OPRT are evaluated using reverse transcription polymer-
ase chain reaction (RT-PCR).
The patients’ clinical data including demographic and
pathological characteristics [19], regimens, drug doses
and treatment duration of adjuvant chemotherapy, and
treatment outcomes including AEs and survivals are col-
lected (Tables 1, 2). Then, relationships among the pro-
tein/mRNA expression and the patients’ clinical data are
analyzed (Figure 1). The primary endpoint is disease free
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survival (RFS), overall survival (OS), and incidence and
severity of AEs.
The registration period is from April 2009 to March
2012, and the follow-up period is 5 years from the en-
rollment of the last subject.Selection of candidate patients
Candidate patients are asked to give informed consent prior
to surgery (Figure 2). Main inclusion criteria are as follows:
1) Clinical stage II or III colon cancer
2) Pathologically confirmed adenocarcinoma
3) Curatively resectable
4) No prior chemotherapy or radiotherapy for colon
cancer
5) Adequate general condition for postoperative
adjuvant chemotherapy
6) No other active malignancies (i.e. diagnosed within
5 years)
7) No contraindication to 5-FUs
Patients who have given written informed consent are
tentatively enrolled at the Foundation for Biomedical
Research and Innovation, Translational Research In-
formatics Center (FBRI-TRI) using a Web-based enroll-
ment system and a “sample number” is issued. A list of
collected information at tentative enrollment is shown
in Table 1.Table 1 A list of collected demographic and pathological data
Items
At tentative enrollment:
- Age at surgery
- Gender
- Date of surgery
- Tumor location
- Scope of LN dissection*
- Surgical approach
- Interval between bowel resection and storage at freezer
At final enrollment:
- Histological type*
- Depth of tumor invasion
- Lymphatic invasion*
- Venous invasion*
- No. of LN examined
- No. of metastatic LN
- Degree of LN metastasis*
*: Japanese Classification of Colorectal Carcinoma, Second English Edition [ref no. 1
LN: lymph node.Collection/storage/submission of tumor samples
Two 5 mm-cubed tissue blocks are taken from the land
wall of the primary tumor immediately after surgery,
and separately put in 2 predefined tubes. One for protein
analysis is put in the blank tube and placed in a freezer.
The other for mRNA analysis is immersed in RNAlaterW
(Life Technologies Japan Ltd., Tokyo, Japan) in the tube.
After rapped with a small air-cushion bag, the tube is
placed in a freezer such that the tissue block is gradually
moistened with RNAlaterW before freezing.
In a preliminary experiment using xenografts, there was
no difference in the sample stabilities between the samples
stored in a deep freezer (−80°C) and those stored in a
freezer for general use (usually at −20°C) for up to 8 weeks
(data not shown). From these observations, samples are
allowed to be stored frozen in a freezer for general use for
up to 8 weeks.
Each tube is labeled with the “sample number” issued
at the tentative enrollment. The samples are collected by
SRL Medisearch Co., Ltd. (SRLM) (Tokyo, Japan), a
commercial laboratory company with a nationwide net-
work. The collected samples are temporarily stored in a
−80°C depository at SRLM, and then sent to the meas-
urement facility (Kamakura Research Laboratories,
Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan).
Final enrollment
After a pathological examination is completed, patients
who meet all of the following criteria are finally enrolled
in the study (Figure 2):at enrollment
Category
Male, Female
C, A, T, D, S, RS
D3, D2, D1, D0
Open surgery, Laparoscopic surgery
<1 hour, 1–3 hours, > 3 hours
pap, tub1, tub2, por1/por2, muc, sig
T1, T2, T3, T4a, T4b
ly0, ly1, ly2, ly3
v0, v1, v2, v3
N1, N2, N3
9].
Table 2 A list of collected data regarding adjuvant chemotherapy
Items Category
Treatment regimen
- Drug names
- Initial dose of each drug (mg/body/day)
Duration of treatment (days)
- Date of starting chemotherapy
- Date of finishing chemotherapy
Reason for finishing chemotherapy Completed the scheduled chemotherapy,
Discontinued by AEs,
Discontinued by the other reason,
Withdrew informed consent
Relative dose intensity ≥75%, 75%>−≥50%, >50%
Most severe grade of each AE (with the date of development)
- Hand foot syndrome None, G1, G2, G3
- Leukocytopenia None, G1-2, G3, G4, G5
- Neutropenia None, G1-2, G3, G4, G5
- Diarrhea None, G1-2, G3, G4, G5
- Vomiting None, G1-2, G3, G4, G5
- Anorexia/Nausea None, G1-2, G3, G4, G5
- Increased AST/ALT None, G1-2, G3, G4, G5
- Hyperbilirubinemia None, G1-2, G3, G4, G5
- Other AEs* G3, G4, G5
*: To be reported only when the severity is grade 3 or higher.
AE: adverse event.
G: grade (the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0).
AST: aspartate aminotransferase.
ALT: alanine aminotransferase.
Tumor Expression
of  biomarkers
2) mRNA of 
TP, DPD, TS, OPRT
1) Protein of 
TP, DPD, EGFR, VEGF
Adjuvant 
chemotherapy
Treatment regimen
Drug dose
Duration of treatment 
Treatment outcomes
.
.
Efficacy: DFS, RFS, OS
Safety: adverse events
Analysis of 
relationship
Pathological stage III colon cancer after curative resection
.
.
.
Figure 1 Study concept of the B-CAST study.
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Clinical stage II, stage III colon cancer
Informed consent
Tentative enrollment
Surgery
- Pathologically confirmed stage III 
- Curatively resected
- Agreed adjuvant chemotherapy
Final enrollment
Adjuvant chemotherapy
Outcome survey
at 1, 3 and 5 years after the last registration
Yes No
5 mm-cubed
tumor blocks
to be stored frozen
2) mRNA of TP, DPD, TS, OPRT 
by RT-PCR
1) Protein of  TP, DPD, EGFR, VEGF 
by ELISA
ineligible
Analysis of relationship
Samples are 
discarded without 
being examinedMeasurement of biomarkers
Figure 2 Study schema of the B-CAST study.
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2) Judged to be curatively resected (R0 resection)
3) Agreed to receive postoperative adjuvant
chemotherapy containing 5-FUs
A list of collected information at final enrollment is
shown in Table 1. A “final registration number” is issued
for each patient after confirming eligibility at FBRI-TRI.
Measurement of biomarkers
The samples from patients who are eligible for “final en-
rollment” are examined in the measurement facility in
accordance with the Standard Operating Procedures.
The samples from ineligible patients (i.e. pathological
stage II) are discarded without being examined.
Measurement of protein expression
The tumor block is wholly homogenized using an ana-
lysis buffer and then centrifuged. Using the resulting
supernatant, the protein expressions of TP, DPD, EGFR,
and VEGF are evaluated by ELISA. For TP and DPD, the
methods established by Chugai Pharmaceutical Co., Ltd.
are used [20,21]. For EGFR and VEGF, Human EGFR
Duo Set ELISA kit and Human VEGF Quantikine ELISA
Kit (R&D Systems Inc., Minneapolis, MN, USA) are
used, respectively. All measurements are performed in
duplicate, and the mean is used for analyses.
Measurement of mRNA expression
The tumor block is wholly homogenized using an analysis
buffer. The total RNA is extracted from the homogenateusing SepasolW-RNA I Super G (Nacalai Tesque Inc.,
Kyoto, Japan) and precipitated with ethanol. The RNA
quality is determined using Experion™ Automated Electro-
phoresis Station (Bio-Rad Laboratories, Inc., Hercules,
CA, USA) and assessed based on the RNA Quality Indica-
tor which is calculated from the observed and reference
values at 18S and 28S peaks using Experion software (Bio-
Rad Laboratories, Inc.). If the RNA quality is adequate,
cDNA is synthesized using 5 μg of total RNA.
The mRNA expressions of TP, DPD, TS, and OPRT
are evaluated by real-time PCR (LightCyclerW480 Real-
Time PCR System, Roche Diagnostics, Mannheim,
Germany) with commercially available primer/probe
sets (Nihon Gene Research Laboratories Inc., Sendai,
Japan). Using glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) as the internal standard, the mRNA
expression of the target gene is quantified. All measure-
ments are performed in duplicate, and the mean will be
used for analyses.
After all eligible samples are examined, the measure-
ment results are submitted to FBRI-TRI data center.
They are not reported to the attending physician, so that
the subsequent treatment is not affected by the measure-
ment results.
Treatment
Adjuvant chemotherapy
The study protocol does not define treatment regimens
and schedule of hospital visits during chemotherapy.
When the chemotherapy is finished, the following infor-
mation regarding adjuvant chemotherapy is reported
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men, dose of each drug, duration of treatment, relative
dose intensity, and AEs. Details of collected information
are shown in Table 2.
Surveillance for relapse
Surveillance for relapse in accordance with a schedule de-
scribed in the JSCCR Guidelines is recommended [3]
(Figure 3). Web-based outcome reporting is conducted 3
times, at 1, 3, and 5 years from the last registration
(Figure 2). Cases of relapse and/or other malignancy are re-
quired to be reported with the date of confirmation and the
site. Cases of death are required to be reported with the
date and cause of death. For surviving patients, the date of
the last confirmation of survival is required to be reported.
Treatment outcomes
Efficacy
DFS (primary endpoint) is defined as the time to relapse,
other malignancies or death, whichever comes first. Pa-
tients alive and free of relapse or other malignancies are
censored at time of the last follow-up. RFS is defined as
the time to relapse or death. Patients alive and free of re-
lapse are censored at time of last follow-up. OS is de-
fined as the time to death. The intervals are calculated
from the date of surgery.
Safety
The types and severities of AEs are evaluated according
to the National Cancer Institute Common Terminology
Criteria for Adverse Events version 3.0 (National Cancer
Institute, Bethesda, MD, USA). HFS is assessed in3
m
o
nths
6
m
o
nths
9
m
o
nths
1
y
1
y
3
m
1
y
6
m
1
y
9
m
2
y
Hospital visit
General/Clinical findings
Tumor marker
(CEA, CA19-9)
Abdominal CT
Chest CT
Colonoscopy
: To be performed if preoperative examinations of the proximal colon 
Figure 3 Recommended surveillance schedule in the Japanese guidelaccordance with the assessment criteria for HFS [22].
The most severe grade of each AE during whole treat-
ment period is reported. The following AEs are required
to be reported as “priority survey items”: leukocytopenia,
neutropenia, HFS, diarrhea, vomiting, anorexia/nausea,
increased aspartate aminotransferase (AST), increased
alanine aminotransferase (ALT), and hyperbilirubinemia.
Other AEs should be reported when the severity is grade
3 or higher.
Statistical matters
Target sample size calculation
As no studies evaluating the relationship between tumor
expression of 5-FU activation/metabolism enzymes and
prognosis numerically through the hazard ratio (HR),
the necessary sample size was calculated through simu-
lation using previous data on tumor TP.
In 6,731 Japanese colon cancer patients, mean loga-
rithmic tumor TP (log TP) determined by ELISA was
4.31 with a standard deviation (SD) of 0.61, with a nor-
mal distribution (unpublished data). We thus assumed
that log TP in the present study population follows a
normal distribution with a similar mean and SD. The
protocol preparation committee concluded that
capecitabine, the efficacy of which may be affected by
tumor TP [12], is recommended to be chosen when in-
creased tumor TP produces a 7% increase in 5-year DFS
rate. In the present study, therefore, the HR of 1-unit de-
crease in log TP for DFS was estimated to be 1.3
(equivalent to a 7% decrease in 5-year DFS rate).
On the assumption that DFS would follow an expo-
nential distribution with a 5-year DFS rate of 70%Time after surgery
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9
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years*, a follow-up period of 5 years, and patient enroll-
ment following a uniform distribution over 2 years* from
the start of the study, a proportional hazard model with
log TP as the covariate and log HR as the true regression
coefficient was applied to produce simulated data with
1,000 iterations for each given HR and sample size. The
proportional hazard model was fitted to these simulated
data to test the significance of the regression coefficient
at a two-sided significance level of α=0.05 based on the
null hypothesis that “tumor TP is not correlated with
DFS.” Statistical Analysis System version 9.1 (SAS insti-
tute Inc., Cary, NC, USA) was used for simulation.
The simulation results showed that a sample size of
950 with a HR of 1.3 would provide a power of 80% or
more. With an estimated dropout rate of approximately
5%, the target sample size of 1,000 was estimated to
evaluate the relationship between tumor TP and DFS in
patients treated with capecitabine. Since three regimens
(capecitabine, UFT/LV, and intravenous 5-FU/LV, re-
spectively) were used, the total target sample size of
3,000 was needed to ensure that similar analyses would
be performed for each of the three regimens.
*: Because of the delayed cumulative pace of patient
enrollment, the registration period was extended in February
2011, from 2 years to 3 years.
Analysis plan
In each treatment group, the Cox proportional hazard
model with covariate as tumor TP is primarily performed
to evaluate significant relationship with DFS. Patients re-
ceiving oxaliplatin containing regimens will be evaluated
separately from those with 5-FU derivatives alone. At 3
years and 5 years after the enrollment of the last subject, an
interim and final analysis is conducted using the Cox pro-
portional hazard model as mentioned above, respectively.
The abovementioned analyses for tumor TP, the primary
variables, are also performed for other measured bio-
markers. Since this is an observational study (not an experi-
mental study), no adjustment for multiplicity is applied.
Secondarily, RFS and OS are also studied in the same
manner as DFS. The relationships between expression of
biomarkers and AEs in each treatment group are also
evaluated by applying a logistic regression model.
And as exprolatory analyses, univariate and multivari-
ate relationships among survivals of each treatment
group, expression of biomarkers and patient characteris-
tics will be evaluated using the Cox proportional hazard
model.
Ethical matters
This study is conducted in accordance with the “Declar-
ation of Helsinki” and “Ethical Guidelines for Clinical
Research”, and has been approved by the InstitutionalReview Boards of each participating institute. Written
informed consent is obtained from all patients before
enrollment.Discussion
The B-CAST study is conducted to prospectively evalu-
ate the relationships between tumor biomarker expres-
sion and treatment outcome in large sample size of stage
III colon cancer patients who received adjuvant chemo-
therapy, in order to identify the patients who benefit
from each 5-FU derivative. A total of 2,128 patients from
the 217 institutions were finally enrolled between April
2009 and March 2012. Follow-up will be completed in
March 2017.
In this study, frozen tumor samples are used to measure
the biomarkers for better quality and quantity of protein/
mRNA than those of paraffin-embedded specimens. And
in considering of the practical versatility, homogenates of
whole specimens of tumor mass, not micro-dissected can-
cer tissues, are used. The most translational research has
conventionally been conducted as mono-institutional re-
search because of difficulty in sample shipment and stor-
age, especially when using frozen samples, resulting in
underpowered studies with a small sample size. The B-
CAST study demonstrated that large-scale, multicenter
translational research using frozen samples was feasible
when the sample shipment and Web-based data collection
were well organized.
The results of the study will provide the large database
of tumor biomarker expression of colon cancer, and
will identify the predictors of benefit from each 5-FU de-
rivative. These observations will contribute to establish
the “personalized therapy” in adjuvant chemotherapy for
colon cancer.
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